Article

Off-Label Drug Lends No Helping Hand for Osteoarthritis

A recent study dashes hopes for an effective treatment of refractory pain.

© OcskayMark/Shutterstock.com

An off-label drug prescribed to treat osteoarthritis of the hand when conventional medication has failed is ineffective, according to new research. The study shows there was no benefit in taking hydroxychloroquine to control debilitating pain when compared with a placebo.

Lead researcher Dr Sarah Kingsbury, from the University of Leeds in the UK, said: "There is some scientific basis as to why hydroxychloroquine could be an effective drug agent. It is known to target inflammation in the joints and is a recognized and licensed treatment for rheumatoid arthritis.

"There is increasing evidence that inflammation is a factor in osteoarthritis. So doctors have used hydroxychloroquine off-label to try and control symptoms and pain.

"But until now, there has not been a large-scale study into whether using hydroxychloroquine works. And our evidence shows that for most patients, it is not an effective treatment."

Dr Kingsbury and fellow researchers recently published the results of their study in the Annals of Internal Medicine.

The study
The study involved 248 patients at 13 NHS hospitals in England: all had the condition for at least 5 years and had changes to the joints in their hands consistent with osteoarthritis.

The participants all reported moderate to severe pain on at least half of the days in the previous 3 months to the study commencing.

The results
The study found that patients initially reported a small reduction in the severity of pain before the improvement plateaued. However, that change was seen in both the group receiving the medication and the group taking the placebo.

Measurements of grip strength and the structural damage existing in patients' joints were similar for both groups.

Take-home message for clinicians
Dr Kingsbury said: "Our findings do not support the current medical practice of giving hydroxychloroquine to patients with hand osteoarthritis."

References:

Kingsbury SR, Tharmanathan P, Keding A, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med. 2018 Feb 20. doi: 10.7326/M17-1430. [Epub ahead of print]

Study challenges use of off-label drug to treat osteoarthritis in hands [press release]. Leeds, England: University of Leeds; February 19, 2018.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.